Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662

被引:497
作者
Leesnitzer, LM
Parks, DJ
Bledsoe, RK
Cobb, JE
Collins, JL
Consler, TG
Davis, RG
Hull-Ryde, EA
Lenhard, JM
Patel, L
Plunket, KD
Shenk, JL
Stimmel, JB
Therapontos, C
Willson, TM
Blanchard, SG
机构
[1] GlaxoSmithKline, Mol Screening, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline, Syst Res, Res Triangle Pk, NC 27709 USA
[3] GlaxoSmithKline, Gene Express & Prot Biochem, Res Triangle Pk, NC 27709 USA
[4] GlaxoSmithKline, Strategy & Operat, Res Triangle Pk, NC 27709 USA
[5] GlaxoSmithKline, High Throughput Chem, Res Triangle Pk, NC 27709 USA
[6] GlaxoSmithKline, Proteom, Res Triangle Pk, NC 27709 USA
[7] GlaxoSmithKline, CVU CEDD, Res Triangle Pk, NC 27709 USA
[8] GlaxoSmithKline, Metab Dis, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1021/bi0159581
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the course of a high throughput screen to search for ligands of peroxisome proliferator activated receptor-gamma (PPARgamma), we identified GW9662 using a competition binding assay against the human ligand binding domain. GW9662 had nanomolar IC50 versus PPARgamma and was 10- and 600-fold less potent in binding experiments using PPARalpha and PPARdelta, respectively. Pretreatment of all three PPARs with GW9662 resulted in the irreversible loss of ligand binding as assessed by scintillation proximity assay. Incubation of PPAR with GW9662 resulted in a change in the absorbance spectra of the receptors consistent with covalent modification. Mass spectrometric analysis of the PPARgamma ligand binding domain treated with GW9662 established Cys(285) as the site of covalent modification. This cysteine is conserved among all three PPARs. In cell-based reporter assays, GW9662 was a potent and selective antagonist of full-length PPARgamma. The functional activity of GW9662 as an antagonist of PPARgamma was confirmed in an assay of adipocyte differentiation. GW9662 showed essentially no effect on transcription when tested using both full-length PPARdelta and PPARalpha. Time-resolved fluorescence assays of ligand-modulated receptor. heterodimerization, coactivator binding, and corepressor binding were consistent with the effects observed in the reporter gene assays. Control activators increased PPAR:RXR heterodimer formation and coactivator binding to both PPARgamma and PPARdelta. Corepressor binding was decreased. In the case of PPARalpha, GW9662 treatment did not significantly increase heterodimerization and coactivator binding or decrease corepressor binding. The experimental data indicate that GW9662 modification of each of the three PPARs results in different functional consequences. The selective and irreversible nature of GW9662 treatment, and the observation that activity is maintained in cell culture experiments, suggests that this compound may be a useful tool for elucidation of the role of PPARgamma in biological processes.
引用
收藏
页码:6640 / 6650
页数:11
相关论文
共 56 条
  • [1] Auwerx J, 1999, CELL, V97, P161
  • [2] PPARγ is required for placental, cardiac, and adipose tissue development
    Barak, Y
    Nelson, MC
    Ong, ES
    Jones, YZ
    Ruiz-Lozano, P
    Chien, KR
    Koder, A
    Evans, RM
    [J]. MOLECULAR CELL, 1999, 4 (04) : 585 - 595
  • [3] Bisphenol A diglycidyl ether (BADGE) is a PPARγ agonist in an ECV304 cell line
    Bishop-Bailey, D
    Hla, T
    Warner, TD
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (04) : 651 - 654
  • [4] BLACKBURN K, 1998, P 46 ASMS C MASS SPE
  • [5] Blanchard SG, 2000, DIABETES, V49, pA97
  • [6] Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library
    Brown, PJ
    Smith-Oliver, TA
    Charifson, PS
    Tomkinson, NCO
    Fivush, AM
    Sternbach, DD
    Wade, LE
    Orband-Miller, L
    Parks, DJ
    Blanchard, SG
    Kliewer, SA
    Lehmann, JM
    Willson, TM
    [J]. CHEMISTRY & BIOLOGY, 1997, 4 (12): : 909 - 918
  • [7] N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.: 3.: Structure-activity relationship and optimization of the N-aryl substituent
    Cobb, JE
    Blanchard, SG
    Boswell, EG
    Brown, KK
    Charifson, PS
    Cooper, JP
    Collins, JL
    Dezube, M
    Henke, BR
    Hull-Ryde, EA
    Lake, DH
    Lenhard, JM
    Oliver, W
    Oplinger, J
    Pentti, M
    Parks, DJ
    Plunket, KD
    Tong, WQ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) : 5055 - 5069
  • [8] N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.: 2.: Structure-activity relationship and optimization of the phenyl alkyl ether moiety
    Collins, JL
    Blanchard, SG
    Boswell, GE
    Charifson, PS
    Cobb, JE
    Henke, BR
    Hull-Ryde, EA
    Kazmierski, WM
    Lake, DH
    Leesnitzer, LM
    Lehmann, J
    Lenhard, JM
    Orband-Miller, LA
    Gray-Nunez, Y
    Parks, DJ
    Plunkett, KD
    Tong, WQ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) : 5037 - 5054
  • [9] L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ -: The role of Cys313 in ligand binding
    Elbrecht, A
    Chen, YL
    Adams, A
    Berger, J
    Griffin, P
    Klatt, T
    Zhang, B
    Menke, J
    Zhou, GC
    Smith, RG
    Moller, DE
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) : 7913 - 7922
  • [10] Examination of micro-tip reversed-phase liquid chromatographic extraction of peptide pools for mass spectrometric analysis
    Erdjument-Bromage, H
    Lui, M
    Lacomis, L
    Grewal, A
    Annan, RS
    McNulty, DE
    Carr, SA
    Tempst, P
    [J]. JOURNAL OF CHROMATOGRAPHY A, 1998, 826 (02) : 167 - 181